business
Radiopharm Selected For Late-Breaking Presentation Of Positive RAD101 Phase 2b Data; Stock Up
Radiopharm Theranostics (RADX) announced positive interim Phase 2b data for RAD101 in suspected recurrent brain metastases, with 93% concordance between PET and MRI across evaluable lesions.
Read full article on Rttnews